INLYTA
As listed in the register: INLYTA
5 mg · tablet
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Axitinib
- Made by
- Pfizer Canada Ulc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (INLYTA). It describes the substance, not this exact product.
Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations.
These receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression.
Axitinib is metabolized primarily in the liver by CYP3A4/5 and to a lesser extent by CYP1A2, CYP2C19, and UGT1A1.
Compared to overnight fasting, administration of INLYTA with a moderate fat meal resulted in 10% lower AUC and a high fat, high-calorie meal resulted in 19% higher AUC.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-03-12
Safety of the active substance
From the US prescribing label for the same active substance (INLYTA). It describes the substance, not this exact product.
Most common adverse reactions (≥20%) are: INLYTA in combination with avelumab: diarrhea, fatigue, hypertension, musculoskeletal pain, nausea, mucositis, palmar-plantar erythrodysesthesia, dysphonia, decreased appetite, hypothyroidism, rash, hepatotoxicity, cough, dyspnea, abdominal pain, and headache.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States2 matching products
European UnionNo exact match for this strength and form
Spain4 matching products
France6 matching products
Netherlands10 matching products
- Axitinib Synthon 5 mg 5 mg · filmomhulde tablet4 makers
- Axitinib Stada 5 mg 5 mg · filmomhulde tablet2 makers
- Axitinib Accord 5 mg filmomhulde tabletten 5 mg · filmomhulde tablet
- Axitinib Sandoz 5 mg 5 mg · filmomhulde tablet
- Axitinib Teva 5 mg 5 mg · filmomhulde tablet
- Inlyta 5mg 5mg · filmomhulde tablet
SwitzerlandNo exact match for this strength and form
Details
| Made by | Pfizer Canada Ulc |
|---|---|
| Active substance | Axitinib |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 5 mg |
| Form | tablet |
| Classification | L01EK01 · Cancer treatments and immune-system medicines |
| Route | oral |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02389649 |
| DPD drug code | 87514 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- tablet2 products
- 1 mg
- 5 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.